[1]张姝,罗洁,许琦,等.贵州地区汉族阿尔茨海默症患者CYP2C19 基因多态性及代谢表型分析[J].现代检验医学杂志,2020,35(05):13-15,37.[doi:10.3969/j.issn.1671-7414.2020.05.004]
　ZHANG Shu,LUO Jie,XU Qi,et al.Analysis of CYP2C19 Gene Polymorphism and Metabolic Phenotype in Alzheimerdisease Patients of Han Nationality in Guizhou[J].Journal of Modern Laboratory Medicine,2020,35(05):13-15,37.[doi:10.3969/j.issn.1671-7414.2020.05.004]
点击复制

贵州地区汉族阿尔茨海默症患者CYP2C19 基因多态性及代谢表型分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第35卷
期数:
2020年05期
页码:
13-15,37
栏目:
论著
出版日期:
2020-11-01

文章信息/Info

Title:
Analysis of CYP2C19 Gene Polymorphism and Metabolic Phenotype in Alzheimerdisease Patients of Han Nationality in Guizhou
文章编号:
1671-7414（2020）05-013-04
作者:
张姝; 罗洁; 许琦; 杨武; 何军
贵州省第二人民医院检验科，贵阳 550004
Author(s):
ZHANG Shu;  LUO Jie;  XU Qi;  YANG Wu; He Jun
Department of Laboratory Medicine, Guizhou Second People’s Hospital, Guiyang 550004，China
关键词:
阿尔茨海默症; 细胞色素P4502C19; 基因多态性
分类号:
R749.16；Q786
DOI:
10.3969/j.issn.1671-7414.2020.05.004
文献标志码:
A
摘要:
目的　探讨贵州地区汉族阿尔茨海默症患者细胞色素P450 2C19(CYP2C19) 基因多态性及代谢表型的分布，为临 床个体化用药提供理论依据。方法　以DNA 微阵列技术检测227 例贵州地区汉族阿尔茨海默症患者CYP2C19 基因多态 性及代谢表型（快代谢型, 中等代谢型, 慢代谢型），用基因计数法计算基因频率和等位基因频率，同时分析基因多态 性与年龄、性别的相关性。结果　在227 例贵州地区汉族阿尔茨海默症患者中，CYP2C19*1/*1,*1/*2,*1/*3,*2/*2,*2/*3 基因型的频率分别为44.9%，38.3%，4.8%，8.8% 和3.1%，快代谢、中代谢和慢代谢3 种代谢表型所占比例分别为 44.9%，43.2% 和11.9%。不同性别及年龄基因型分布比较差异无统计学意义（χ2=4.314，4.435，均P>0.05），不同年 龄段CYP2C19 代谢表型分布差异有统计学意义（χ2=32.053，P<0.001）。结论　贵州地区汉族阿尔茨海默症患者中有 较多的CYP2C19 代谢功能缺失基因，检测CYP2C19 基因多态性及代谢表型能为临床个体化用药提供依据，提高临床 疗效，减少不良反应发生。
Abstract:
Objective　To explore the distribution of cytochrome P450 2C19 (CYP2C19) gene polymorphisms and metabolic phenotypes in Alzheimer disease patients of Han nationality in Guizhou, and provide a theoretical basis for clinical individualized medication. Methods　DNA microarray technology was used to detect CYP2C19 gene polymorphism and metabolic phenotype (fast metabolic type, medium metabolic type, slow metabolic type) in 227 Alzheimer disease patients of Han nationality in Guizhou Area. Gene frequency and allele frequency were calculated by gene counting method, and the correlation between gene polymorphism and age and sex was analyzed. Results　Among 227 Alzheimer diseasepatients of Han nationality in Guizhou,the frequency of CYP2C19*1/*1,*1/*2,*1/*3,*2/*2,*2/*3 genotypes were 44.9%, 38.3%, 4.8%, 8.8% and 3.1% respectively, and the proportions of fast metabolism, medium metabolism and slow metabolism were 44.9%, 43.2% and 11.9%, respectively. There was no statistically significant difference in the distribution of genotypes between different genders and ages (χ2=4.314, 4.435, all P>0.05), and there was a statistically significant difference in the distribution of CYP2C19 metabolic phenotypes between different ages (χ2=32.053, P<0.001). Conclusion　There were more CYP2C19 metabolic function-deficient genes in Alzheimerdisease patients of Han nationality in Guizhou. Detection of CYP2C19 gene polymorphism and metabolic phenotype can provide a basis for clinical individualized medication, improve clinical efficacy, and reduce the occurrence of adverse reactions.

参考文献/References:

[1] 张爱玲，胡欣，杨莉萍．亚洲健康人群CYP2C19 基因型发生率的合并分析[J]. 中国循证医学杂志， 2014,14（4）:427-434． ZHANG Ailing, HU Xin, YANG Liping. Genotype frequencies of CYP2C19 in healthy Asian populations： A synthetic analysis [J]. Chinese Journal of Evidence- based Medicine, 2014, 14(4): 427-434.
[2] BERCHTOLD N C, COTMAN C W. Evolution in the conceptualization of dementia and Alzheimer’s disease: Greco-Roman period to the 1960s[J]. Neurobiology of Aging, 1998, 19(3): 173-189.
[3] PATTERSON C, World Alzheimer Report 2018.The state of the art of dementia research:New frontiers[R]. London：Publ ished by Alzheimer ’s Disease International（AID）, 2018.
[4] 王英全，梁景宏，贾瑞霞，等．2020-2050 年中国 阿尔茨海默病患病情况预测研究[J]．阿尔茨海默病 及相关病杂志, 2019, 2（1）: 289-298． WANG Yingquan, LIANG Jinghong, JIA Ruixia, et al. Alzheimer disease in China(2015-2050) estimated using the 1% population sampling survey in 2015 [J]. China Journal of Alzheimer’s Disease and Related Disorders,2019,2(1):289-298.
[5] 王燕娟，任庆国，张志珺．SSRI 类抗抑郁剂在阿尔 茨海默病中的应用研究进展[J]. 东南大学学报( 医 学版), 2014, 33（4）: 504-508． WANG Yanjuan, REN Qingguo, ZHANG Zhijun. Advances in the application of SSRI antidepressants in Alzheimer’s disease [J]. Journal of Southeast University (Medical Science Edition), 2014, 33(4): 504-508.
[6] 靳庆敏，葛茂宏．CYP2C19 基因多态性对抗抑郁 剂代谢影响的研究进展[J]. 精神医学杂志,2017,30 （4）:297-299． JIN Qingmin, GE Maohong. Research progress of the effect of CYP2C19 gene polymorphism on the metabolism of antidepressants [J]. Journal of Psychiatry, 2017, 30(4): 297-299.
[7] WANG Jiuhui, LIU Zhaoqian, WANG Wei, et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19[J]. Clinical Pharmacology and Therapeutics, 2001, 70(1): 42-47.
[8] 张丽娟，田芳．CYP2 C19 遗传多态性对中国健康 受试者西酞普兰代谢的影响[J]．中国临床药理学杂 志,2014（4）:324-326, 331． ZHANG Lijuan, TIAN Fang. Effects of the genetic polymorphism CYP2 C19 on pharmacokinetics of citalopram in Chinese healthy volunteers [J]. The Chinese Journal of Clinical Pharmacology,2014, (4): 324-326, 331.
[9] 谢焕山，陈宏镇，王占璋，等．基于细胞色素P450 基因多态性的文拉法辛药代动力学和安全性评价[J]. 中国临床药理学杂志,2019,35（19）:2426-2429, 2438. XIE Huanshan, CHEN Hongzhen, WANG Zhanzhang, et al. Evaluation of pharmacokinetics and safety of venlafaxine based on cytochrome P450 gene polymorphism [J]. The Chinese Journal of Clinical Pharmacology, 2019, 35(19) :2426-2429,2438.
[10] 谢燕，宋明芬，章隆，等．CYP2C19 基因多态性对 精神分裂症患者丙戊酸血药浓度的影响[J]. 中国现 代应用药学, 2016, 33（5）:653-657． XIE Yan, SONG Mingfen, ZHANG Long, et al. Effect of CYP2C19 genetic polymorphism on blood concentration of valproic acid in schizophrenia [J]. Chinese Journal of Modern Applied Pharmacy , 2016, 33(5): 653-657 .
[11] XIE H G, HUANG S L, XU Z H, et al. Evidence for the effect of gender on activity of (S)-mephenytoin 4’-hydroxylase (CYP2C19) in a Chinese population[J]. Pharmacogenetics, 1997, 7(2): 115-119.
[12] 黄博，任凌雁，任映，等．贵州少数民族CYP2C19 基因多态性分布[J]. 深圳中西医结合杂志, 2019, 29 （20）:3-5． HUANG Bo, REN Lingyan, REN Ying, et al. Distribution of CYP2C19 gene polymorphism in Guizhou minority[J]. Shenzhen Journal of Integrated Traditional Chinese and Western Medicine, 2019, 29(20): 3-5.
[13] 黄丽云，符青，陈冬琳．CYP2C19 基因多态性对氯 吡格雷抗血小板治疗疗效的影响[J]．中国医院药学 杂志, 2019, 39（6）: 624-627． HUANG Liyun, FU Qing, CHEN Donglin. Effect of CYP2C19 gene polymorphism on the efficacy of clopidogrel antiplatelet therapy[J]. Chinese Journal of Hospital Pharmacy, 2019, 39(6): 624-627.
[14] 平军娇，高永双，邓顺顺，等．广东省中山地区汉 族精神类疾病患者药物基因型及代谢表型分布研究 [J]. 现代检验医学杂志, 2019, 34（3）: 15-20,24. PING Junjiao, GAO Yongshuang, DENG Shunshun, et al. Research on characteristics of drug genotypes and metabolic phenotypes in Chinese Han patients with severe mental illness in Zhongshan area of Guangdong province [J]. Journal of Modern Laboratory Medicine, 2019, 34(3): 15-20, 24.
[15] 蒋燕成，陈辉华，陈雅斌，等．中国福建泉州地区 心脑血管患者CYP2C19,ABCB1 基因多态性的检测 分析[J]. 现代检验医学杂志, 2019, 34（6）: 10-15. JIANG Yancheng, CHEN Huihua, CHEN Yabin, et al. Detection and analysis of CYP2C19, ABCB1 gene polymorphism in patients with cardiovascular and Cerebrovascular Diseases in Quanzhou of Fujian, China [J]. Journal of Modern Laboratory Medicine, 2019, 34(6): 10-15.

相似文献/References:

[1]王鹏飞a,陈长英a,靳玉娟b,等.阿尔茨海默症患者血清miR-211 和miR-202 表达水平及其与认知功能、焦虑抑郁情绪的相关性研究[J].现代检验医学杂志,2024,39(02):129.[doi:10.3969/j.issn.1671-7414.2024.02.024]
　WANG Pengfeia,CHEN Changyinga,JIN Yujuanb,et al.Serum miR-211 and miR-202 Expression Levels in Alzheimer’s Disease Patients and Their Correlation with Cognitive Function, Anxiety and Depression[J].Journal of Modern Laboratory Medicine,2024,39(05):129.[doi:10.3969/j.issn.1671-7414.2024.02.024]

备注/Memo

备注/Memo:
作者简介：张姝（1982-），女，主管检验师，研究方向：临床微生物及分子生物学，E-mail:2779982173@qq.com。
通讯作者：何军（1978-），男，主任技师，研究方向：精神疾病检验及免疫学，E-mail:gzgyhjjj@163.com。
更新日期/Last Update: 2020-10-30